Dominik Steubl1,2, Petra Buzkova3, Pranav S Garimella4, Joachim H Ix4, Prasad Devarajan5, Michael R Bennett5, Paulo H M Chaves6, Michael G Shlipak7, Nisha Bansal8, Mark J Sarnak1. 1. Division of Nephrology, Department of Medicine, Tufts Medical Center, Tufts University, Boston, MA, USA. 2. Division of Nephrology, Klinikum rechts der Isar, Technische Universität München, München, Germany. 3. Department of Biostatistics, University of Washington, Seattle, WA, USA. 4. Division of Nephrology, University of California, San Diego, San Diego, CA, USA. 5. Department of Nephrology and Hypertension, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, USA. 6. Benjamin Leon Center for Geriatric Research and Education, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. 7. Division of General Internal Medicine, University of California, San Francisco, San Francisco, CA, USA. 8. Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Uromodulin (UMOD) is released by renal tubular cells into the serum (sUMOD) and urine. Lower urine UMOD has been linked to mortality and cardiovascular disease but much less is known about sUMOD. We evaluated the association of sUMOD with these outcomes in community-dwelling older adults. METHODS: We measured sUMOD in a random subcohort of 933 participants enrolled in the Cardiovascular Health Study. The associations of sUMOD with all-cause mortality, incident heart failure (HF) and incident cardiovascular disease (CVD; myocardial infarction, stroke and mortality due to coronary disease or stroke) were evaluated using multivariable Cox regression, adjusting for study participants' demographics, estimated glomerular filtration rate (eGFR), albuminuria and CVD risk factors. Generalized additive models with splines were used to address the functional form of sUMOD with outcomes. Due to nonlinear associations of sUMOD with all outcomes, 2.5% of the values on either end of the sUMOD distribution were excluded from the analyses, limiting the range of sUMOD to 34.3-267.1 ng/mL. RESULTS: The mean age was 78 ± 5 years, 40% were male, sUMOD level was 127 ± 64 ng/mL, eGFR was 63 mL/min/1.73 m2 and 42% had CKD defined as eGFR <60 mL/min/1.73 m2. Patients in the lower sUMOD quartiles had lower eGFR and higher albuminuria (P < 0.01, respectively). During a median follow-up of 9.9 years, 805 patients died, 283 developed HF and 274 developed CVD. In multivariable analysis, higher sUMOD was significantly associated with a lower hazard for mortality {hazard ratio [HR] 0.89 [95% confidence interval (CI) 0.80-0.99] per 1 standard deviation (SD) higher sUMOD}, CVD [HR 0.80 (95% CI 0.67-0.96)] and the composite endpoint [HR 0.88 (95% CI 0.78-0.99)]; the association with HF was not statistically significant [HR 0.84 (95% CI 0.70-1.01)]. CONCLUSION: Higher sUMOD is independently associated with a lower risk for mortality and CVD in older adults.
BACKGROUND:Uromodulin (UMOD) is released by renal tubular cells into the serum (sUMOD) and urine. Lower urine UMOD has been linked to mortality and cardiovascular disease but much less is known about sUMOD. We evaluated the association of sUMOD with these outcomes in community-dwelling older adults. METHODS: We measured sUMOD in a random subcohort of 933 participants enrolled in the Cardiovascular Health Study. The associations of sUMOD with all-cause mortality, incident heart failure (HF) and incident cardiovascular disease (CVD; myocardial infarction, stroke and mortality due to coronary disease or stroke) were evaluated using multivariable Cox regression, adjusting for study participants' demographics, estimated glomerular filtration rate (eGFR), albuminuria and CVD risk factors. Generalized additive models with splines were used to address the functional form of sUMOD with outcomes. Due to nonlinear associations of sUMOD with all outcomes, 2.5% of the values on either end of the sUMOD distribution were excluded from the analyses, limiting the range of sUMOD to 34.3-267.1 ng/mL. RESULTS: The mean age was 78 ± 5 years, 40% were male, sUMOD level was 127 ± 64 ng/mL, eGFR was 63 mL/min/1.73 m2 and 42% had CKD defined as eGFR <60 mL/min/1.73 m2. Patients in the lower sUMOD quartiles had lower eGFR and higher albuminuria (P < 0.01, respectively). During a median follow-up of 9.9 years, 805 patients died, 283 developed HF and 274 developed CVD. In multivariable analysis, higher sUMOD was significantly associated with a lower hazard for mortality {hazard ratio [HR] 0.89 [95% confidence interval (CI) 0.80-0.99] per 1 standard deviation (SD) higher sUMOD}, CVD [HR 0.80 (95% CI 0.67-0.96)] and the composite endpoint [HR 0.88 (95% CI 0.78-0.99)]; the association with HF was not statistically significant [HR 0.84 (95% CI 0.70-1.01)]. CONCLUSION: Higher sUMOD is independently associated with a lower risk for mortality and CVD in older adults.
Authors: Radmila Micanovic; Shehnaz Khan; Danielle Janosevic; Maya E Lee; Takashi Hato; Edward F Srour; Seth Winfree; Joydeep Ghosh; Yan Tong; Susan E Rice; Pierre C Dagher; Xue-Ru Wu; Tarek M El-Achkar Journal: J Am Soc Nephrol Date: 2017-11-27 Impact factor: 10.121
Authors: Peter A McCullough; Thomas M Beaver; Elliott Bennett-Guerrero; Michael Emmett; Gregg C Fonarow; Abhinav Goyal; Charles A Herzog; Mikhail Kosiborod; Biff F Palmer Journal: Rev Cardiovasc Med Date: 2014 Impact factor: 2.930
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: B M Psaty; L H Kuller; D Bild; G L Burke; S J Kittner; M Mittelmark; T R Price; P M Rautaharju; J Robbins Journal: Ann Epidemiol Date: 1995-07 Impact factor: 3.797
Authors: Dominik Steubl; Petra Buzkova; Joachim H Ix; Prasad Devarajan; Michael R Bennett; Paolo H M Chaves; Michael G Shlipak; Nisha Bansal; Mark J Sarnak; Pranav S Garimella Journal: Nephrology (Carlton) Date: 2019-12-27 Impact factor: 2.506
Authors: Dominik Steubl; Markus P Schneider; Heike Meiselbach; Jennifer Nadal; Matthias C Schmid; Turgay Saritas; Vera Krane; Claudia Sommerer; Seema Baid-Agrawal; Jakob Voelkl; Fruzsina Kotsis; Anna Köttgen; Kai-Uwe Eckardt; Jürgen E Scherberich Journal: Clin J Am Soc Nephrol Date: 2020-04-14 Impact factor: 8.237
Authors: Gabriella-Salome K Armstrong; Jacqueline A Frank; Christopher J McLouth; Ann Stowe; Jill M Roberts; Amanda L Trout; Justin F Fraser; Keith Pennypacker Journal: J Exp Neurol Date: 2021-03
Authors: Stephan Kemmner; Christopher Holzmann-Littig; Helene Sandberger; Quirin Bachmann; Flora Haberfellner; Carlos Torrez; Christoph Schmaderer; Uwe Heemann; Lutz Renders; Volker Assfalg; Tarek M El-Achkar; Pranav S Garimella; Jürgen Scherberich; Dominik Steubl Journal: J Clin Med Date: 2021-06-11 Impact factor: 4.241
Authors: Cornelia Then; Christian Herder; Holger Then; Barbara Thorand; Cornelia Huth; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Andreas Lechner; Jürgen Scherberich; Jochen Seissler Journal: Clin Kidney J Date: 2020-09-06